Dong-A Vows Legal Steps As Korea Imposes Heavy Penalties Over Rebates
Korea temporarily suspends reimbursement of drugs involved in Dong-A ST’s alleged illegal rebate payments to doctors, raising concerns from the industry whether the new measures are appropriate. The company concedes it violated the Pharmaceutical Affairs Act but vows to seek legal redress as it claims there are substantial issues with the punitive measures.
You may also be interested in...
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.
Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.